TROP2 dysregulation has been implicated across multiple malignancies, including triple-negative breast cancer, urothelial carcinoma, endometrial cancer, and lung cancers, with IHC studies demonstrating moderate to high TROP2 expression in SCLC. This evidence concerns the gene TACSTD2 and lung carcinoma.